The mono-CD14+CD16+ cells in patients with mild COVID-19 expressed higher levels of a fatty acid-related gene (FABP5), whereas in patients with severe COVID-19, these cells expressed higher levels of glycolysis-related genes (PKM, TALDO1, and LDHA), a PPP-related genes (PGD), a fatty acid-related gene (ASCL1), a cysteine and methionine metabolism-related gene (MAT2A), and an alanine, aspartate and glutamate metabolic related gene (GLUL), as wells as lower levels of lysine metabolism-related genes (KMT2C, SETD2, KMT2E and NSD1). The gene discussed is CD14; the disease is COVID-19.